Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

Find a Research Study

A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T-ALL/T-LLy) (ALLO-T-DART)

To determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high-risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).


Why this Research Matters

A Phase 1 trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high-risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).


Who can Participate

1. T-cell acute lymphoblastic leukemia in second or subsequent remission (≤ 5% blasts) 2. Relapsed T-cell lymphoblastic lymphoma with complete response after re-induction therapy


Study ID

Protocol Number: 24-0339

More information available at ClinicalTrials.gov: NCT04972942


Meet the Team

Image of Principal Investigator

Taymour Hammoudi, MD, PhD

Principal Investigator